Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ApollomicsAPLM +1.84%31 Debt-to-EBITDA is 0.19 as of Dec. 2025. GuruFocus rates APLM with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 291 Biotechnology companies, Apollomics ranks worse than 343642.27% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Apollomics's Debt-to-EBITDA or its related term are showing as below:
APLM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.06 Med: -0.02 Max: 0
Current: -0.06
APLM's Debt-to-EBITDA is ranked worse than 100% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs APLM: -0.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Apollomics Debt-to-EBITDA Related Terms
Apollomics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Apollomics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APLM vs HYPD, MGX, KALA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Apollomics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apollomics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apollomics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Apollomics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Apollomics (APLM) has a Debt-to-EBITDA of 0.19 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Apollomics. According to the industry distribution chart, Apollomics ranks #999999 out of 291 companies in the Biotechnology industry.
Is Apollomics' Debt-to-EBITDA too high?
Apollomics' current Debt-to-EBITDA is 0.19. The Biotechnology industry median Debt-to-EBITDA is 1.14. Apollomics' value of 0.19 is 83.3% below this industry median. Based on the distribution chart, Apollomics ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Debt-to-EBITDA compare to HYPD and MGX?
According to the Biotechnology industry distribution chart, Apollomics ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Apollomics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. Apollomics' value of 0.19 is 83.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apollomics's current Debt-to-EBITDA of 0.19 is 83.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Apollomics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apollomics's current Debt-to-EBITDA is 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLM) has a current Debt-to-EBITDA of 0.19. The current Debt-to-EBITDA is 0.19 and 83.3% below the Biotechnology industry median of 1.14. Apollomics' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Apollomics (APLM), the current Debt-to-EBITDA is 0.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score
Get the complete analysis for APLM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APLM has been successfully added to your 
